BIIB has been the topic of several other research reports. Royal Bank of Canada set a $242.00 target price on shares of Biogen and gave the company a hold rating in a research note on Friday, September 6th. Cowen restated a buy rating and set a $275.00 target price on shares of Biogen in a research note on Tuesday, July 30th. Credit Suisse Group began coverage on shares of Biogen in a research note on Monday, May 20th. They set an underperform rating and a $198.00 target price on the stock. Wedbush began coverage on shares of Biogen in a research note on Wednesday, May 22nd. They set a neutral rating and a $231.00 target price on the stock. Finally, Citigroup restated a neutral rating on shares of Biogen in a research note on Thursday, May 23rd. Three investment analysts have rated the stock with a sell rating, twenty-four have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $270.00.
Shares of NASDAQ BIIB traded up $4.32 during midday trading on Thursday, hitting $236.63. The stock had a trading volume of 1,687,099 shares, compared to its average volume of 1,801,268. The business’s 50 day moving average is $231.19 and its 200-day moving average is $243.05. The company has a market cap of $42.98 billion, a P/E ratio of 9.03, a PEG ratio of 0.86 and a beta of 1.01. Biogen has a 52 week low of $215.77 and a 52 week high of $358.41. The company has a quick ratio of 2.22, a current ratio of 2.46 and a debt-to-equity ratio of 0.49.
Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Tuesday, July 23rd. The biotechnology company reported $9.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $7.58 by $1.57. Biogen had a net margin of 37.62% and a return on equity of 44.89%. The company had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter last year, the firm earned $5.80 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, analysts expect that Biogen will post 32.38 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Trustcore Financial Services LLC increased its holdings in Biogen by 152.3% in the 2nd quarter. Trustcore Financial Services LLC now owns 111 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 67 shares in the last quarter. Resources Investment Advisors Inc. increased its holdings in Biogen by 500.0% in the 1st quarter. Resources Investment Advisors Inc. now owns 120 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 100 shares in the last quarter. Weaver Consulting Group purchased a new stake in Biogen in the 1st quarter worth approximately $28,000. Ruggie Capital Group purchased a new stake in Biogen in the 2nd quarter worth approximately $33,000. Finally, JJJ Advisors Inc. purchased a new stake in Biogen in the 2nd quarter worth approximately $35,000. Hedge funds and other institutional investors own 86.55% of the company’s stock.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
Read More: How to invest in a bear market
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.